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Frontotemporal dementia is accompanied by motor neuron disease (FTDþMND) in 10% of cases. There is
accumulating evidence for a clinicopathological overlap between FTD and MND based on observations of famil-
ial aggregation and neuropathological findings of ubiquitin-positive neuronal cytoplasmatic inclusions (NCI) in
lowermotor neurons, hippocampus and neocortex in both conditions. Several familial forms exist with different
genetic loci and defects.We investigated the familial aggregation and clinical presentation of FTDþMND cases
in a large cohort of 368 FTD patients in the Netherlands. Immunohistochemistry of available brain tissue of
deceased patients was investigated using a panel of antibodies including ubiquitin, p62 and TAR DNA-binding
protein of 43kDa antibodies.
A total of eight patients coming from six families had a family history positive for FTDþMND (mean age at
onset 53.2 8.4 years). Five patients presented with behavioural changes and cognitive changes followed by
motor neuron disease, whereas symptoms ofmotor neuron disease were the presenting features in the remain-
ing three patients. Other affected relatives in these families showed dementia/FTD, MND or FTDþMND
reflecting the clinical interfamilial variation.Nomutations were identified in any of the candidate genes, includ-
ing Superoxide Dismutase 1, dynactin, angiogenin, Microtubule-Associated Protein Tau, valosin-containing protein
and progranulin. Available brain tissue of five patients with familial FTDþMND showed NCI in hippocampus,
neocortex and spinal cord in all, and neuronal intranuclear inclusions (NII) in two brains. TDP-43 antibody
showed robust staining of neuronal inclusions similar in distribution and morphology to NCI and NII.
Additionally, TDP-43 antibody also stained ubiquitin-negative glial inclusions in the basal striatum of one case.
In conclusion, there exists considerable clinical variation within families with FTDþMND, which may be deter-
mined by other genetic or environmental factors.NII are also found in some cases of familial FTDþMNDwith-
out Progranulin mutations. The observation of glial TDP-43 positive inclusions in one brain is very interesting,
although their pathophysiological significance is yet unknown.
Keywords: frontotemporal dementia; motor neuron disease; TDP-43; progranulin
Abbreviations: FTD¼ frontotemporal dementia; GFAP¼glial fibrillary acidic protein; HMPAO¼ 99mTc-hexamethyl
propyleneamine oxime; MND¼motor neuron disease; NCI¼neuronal cytoplasmatic inclusions; NII¼neuronal intranuclear
inclusions; PML¼ promyelocytic leukaemia protein; SPECT¼single photon emission computed tomography; SUMO-1¼small
ubiquitin modifier-1; TDP-43; TAR DNA-binding protein of 43 kDa; ub-positive¼ubiquitin-positive
Received November 28, 2006. Revised January 24, 2007. Accepted January 30, 2007. Advance Access publication March 14, 2007
doi:10.1093/brain/awm024 Brain (2007), 130, 1375^1385
 The Author (2007). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
 at K
atholieke U
niversiteit on July 13, 2012
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Introduction
Frontotemporal dementia (FTD) is clinically, pathologically
and genetically a heterogeneous disorder characterized by
behavioural changes and cognitive decline. FTD has often,
but not always, a presenile onset (Rosso et al., 2003).
Semantic dementia and non-fluent progressive aphasia are
clinical variants of FTD. In 5–10% of cases, FTD is
preceded, accompanied or followed by signs of motor
neuron disease (FTDþMND) (Rosso et al., 2003; Goldman
et al., 2005; Johnson et al., 2005). Several studies have
shown that survival in patients with FTDþMND is
significantly shorter than in FTD patients without features
of motor neuron disease (Hodges et al., 2003; Bigio et al.,
2004; Josephs et al., 2005).
There is accumulating evidence supporting a clinical
overlap between FTD and MND by observations, as
cognitive dysfunction is present in 30–50% of patients
with amyotrophic lateral sclerosis (ALS) (Massman et al.,
1996; Lomen-Hoerth et al., 2002, 2003; Ringholz et al.,
2005). Further arguments for this overlap are the
occurrence of primary progressive aphasia (Caselli et al.,
1993; Tsuchiya et al., 2000) and the presence of fronto-
temporal atrophy in patients with MND (Konagaya et al.,
1998; Tsuchiya et al., 2001; Tan et al., 2003). From an
epidemiological perspective, the significantly higher risk of
dementia in relatives of MND patients compared to
controls suggests a shared susceptibility (Majoor-Krakauer
et al., 1994).
Pathologically, FTDþMND is characterized by neuronal
loss in brainstem nuclei and anterior horns of the spinal
cord, with or without corticospinal tract degeneration
(Josephs et al., 2006a). The presence of ubiquitin-positive
(ub-positive) inclusions in lower motor neurons of the
spinal cord and granular cells of the hippocampus have
originally been reported in FTDþMND (Okamoto et al.,
1992; Wightman et al., 1992), and has been confirmed in
other pathological series (Jackson et al., 1996; Katsuse and
Dickson, 2005; Forman et al., 2006; Josephs et al., 2006b;
Kersaitis et al., 2006). Ub-positive inclusions are also found
in 40–60% of FTD cases without MND (Josephs et al.,
2004; Johnson et al., 2005), in hereditary FTD with and
without progranulin (PGRN) mutations (Rosso et al., 2001a;
Baker et al., 2006; Cruts et al., 2006) and in semantic
dementia (Rossor et al., 2000). These observations have
further strengthened the concept that FTD and MND are
part of a spectrum (Ince and Morris, 2006). The recent
identification of TAR DNA-binding protein of 43 kDa
(TDP-43) as constituent of ub-positive inclusions in both
FTD and sporadic ALS is another argument for an overlap
in pathology between these two entities (Neumann et al.,
2006).
Genetic factors play an important role in FTD and MND.
Families with an autosomal dominant form of FTDþMND
have been described in previous reports (Gunnarsson et al.,
1991; Polvikoski et al., 2003; Martinaud et al., 2005).
Several genetic defects have been identified, including
Chromatin-Modifying Protein 2b gene (CHMP2B)
(Skibinski et al., 2005; Parkinson et al., 2006), and dynactin
gene (DCTN1) (Munch et al., 2005). Mutations in the
valosin-containing protein gene are associated with FTD,
Paget’s disease and myopathy (Kovach et al., 2001; Watts
et al., 2004). Other genetic loci for FTDþMND are found
on chromosome 9p (Watts et al., 2004; Morita et al., 2006;
Vance et al., 2006), 9q (Hosler et al., 2000) and 17q
(Wilhelmsen et al., 2004).
In this study, we investigated the familial aggregation,
clinical features and genetic defect of FTDþMND in a
large Dutch cohort of 368 FTD patients. Additionally,
immunohistochemistry of available brain tissue was carried
out by means of a panel of antibodies, including ubiquitin-,
tau, p62 and TDP-43 antibodies to determine the
pathological phenotype.
Material and methods
Clinical data
Since 1994, three hundred and sixty-eight patients have been
recruited in the Dutch prospective FTD cohort, as previously
described by Rosso and Stevens (Stevens et al., 1998; Rosso et al.,
2003). The cohort study includes a detailed clinical history
regarding the onset and course of the disease obtained from the
spouses and first-degree relatives by using a checklist of
behavioural and cognitive changes and motor symptoms. The
age at onset was defined as the age at which the first symptom
compatible with the diagnosis FTD or MND was observed by a
close relative or caretaker.
All patients underwent a routine neurological examination with
special attention for the presence of extrapyramidal and upper and
lower motor signs. The clinical diagnosis MND was based on the
presence of the following abnormalities at neurological examina-
tion: swallowing problems and dysarthria, muscular wasting or
weakness and fasciculations in tongue and extremities (Table 1).
Ambulant patients, who visited our outpatient clinic, underwent
neuropsychological evaluation and neuroimaging [magnetic reso-
nance imaging (MRI) or single photon emission computed
tomography (SPECT) with 99mTc-hexamethyl propyleneamine
oxime (HMPAO), or both]. Neuropsychological evaluation
included testing of intelligence, language functions (Boston
Naming Test), attention and concentration, executive and
visuospatial functions. Electromyography was carried out in
ambulant patients visiting our outpatient clinic with muscle
weakness or other signs suggestive of lower motor neuron disease.
For patients visited in nursing homes by the research physician,
data collection was limited to detailed clinical history and
neurological examination, whereas clinical, neuropsychological
and neurophysiological data, as well as hard copies of neuroimag-
ing, already available from medical records, were reviewed. The
diagnosis FTD was based on the criteria of Lund and Manchester
(Neary et al., 1998; The Lund and Manchester Groups, 1994) and
included (1) a progressive behavioural disorder with insidious
onset; (2) affective symptoms; (3) speech disorder; (4) preserved
spatial orientation and praxis and (5) selective frontotemporal
atrophy (CT/MRI) or selective frontotemporal hypoperfusion
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(SPECT) on neuroimaging. Consensus about the clinical diagnosis
between research physician, neurologist and neuropsychologist was
obtained, and in case of uncertain diagnosis, the final decision was
made based on supplementary clinical, neuropsychological and
neuroimaging data later in the course of the disease. The pattern
of cerebral atrophy on CT or MRI was evaluated, and patients
were classified according to the predominance of either frontal or
temporal atrophy as described previously (Rosso et al., 2001b).
Left–right asymmetry was considered to be present if there was at
least one grade difference.
Data on family history were obtained by a structured
questionnaire provided by spouse or first-degree relative. The
family history was defined as positive if there was at least one
first-degree relative with dementia, parkinsonism or motor neuron
disease before the age of 80 years. Family history was to be
considered as suggestive for an autosomal dominant pattern of
inheritance if at least three individuals over two or more
generations were affected. All patients were followed up by visits
to our outpatient department or by telephone interview of
relatives. The duration of the disease was determined in all
patients who died during the course of the study. Each patient,
spouse or first-degree relative of the patient gave written informed
consent for blood sampling for extracting genomic DNA from
peripheral lymphocytes according to the standard procedures.
From this cohort, we selected all patients with familial
FTDþMND, defined as: (1) patients with FTDþMND and a
family history positive for dementia or MND and (2) FTD
patients with a family history positive for MND. The clinical
diagnosis of MND in FTD patients was defined by the presence of
upper or lower (bulbar and spinal) motor neuron symptoms, or
both, documented by neurological examination with or without
electromyographic testing. The clinical diagnosis in affected family
members was based on clinical data obtained from relatives,
available data from medical records and/or autopsy reports.
Genetic analysis
DNA was isolated from peripheral blood cells according to
standard procedure. MAPT, CHMP2B and PGRN genes were
sequenced in all patients with familial FTDþMND; PCR and
sequencing conditions for all coding exons of these genes have
been previously described (Rizzu et al., 1999; Skibinski et al., 2005;
Baker et al., 2006). Novel sequence variants were analysed in a
minimum of 380 chromosomes from healthy individuals of
matched ethnicity and gender. Control DNA was screened by
PCR amplification of the specific exon followed by direct
sequencing. The 13 exons of PGRN gene including intron/exons
boundaries were amplified from genomic DNA by PCR and
directly sequenced in both strands.
Additionally, patients with familial FTDþMND were separately
screened for mutations in superoxide dismutase (SOD1), angiogenin
(ANG), Valosin-Containing Protein (VCP) gene and Dynactin
(DCTN1) gene. Exons of the ANG and DCTN1 genes including
intron/exons boundaries were amplified from genomic DNA by
PCR and directly sequenced on both strands. PCR reactions were
performed in 25 ml containing 1 Invitrogen PCR buffer, 1.5mM
MgCl2, 250mM of each dNTP, 0.5U Platinum Taq polymerase
and 0.4 mM of primers. 10% DMSO was added to amplify exon 1
and exon 2 of the ANG gene. The annealing temperature for all
primer pairs was 58C. Direct sequencing of both strands was
performed using the Big Dye Terminator chemistry version 3.1
and loaded on an ABI 3730 automated sequencer.
Immunohistochemistry
Brain autopsy was carried out by the Netherlands Brain Bank
within 4 h after death according to Legal and Ethical Code of
Conduct of the Netherlands Brain Bank. Tissue blocks were taken
from the frontal, temporal, parietal and occipital cortex,
hippocampus, striatum, thalamus, substantia nigra, locus
Table 1 Clinical features of index patients
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6
II : 3 II : 1 II : 2 II : 4 II : 1 II : 1 II : 2 II : 4
Sex Female Female Male Male Male Female Female Female
Age at onset (years) 61 63 51 63 54 48 40 64
Age at death (years) 64 alive 53 69 57 51 43 68
Onset disease MND FTD FTD FTD MND MND FTD FTD
Presenting symptoms
Language dysfunction   þ þ   þþ þþ
Executive impairment  þþ þþ    þþ þ
Behavioural problems  þ þþ þþ   þþ þþ
Memory loss  þ þ þ þ  þ þ
Weakness, dysarthria þ    þ þ  
Neurological examination
Tongue atrophy þ   þ  þ þ 
Tongue fasciculations þ  þ þ  þ þ 
Muscular atrophy þ  þ þ þ þ  
Muscular weakness þ  þ þ þ þ þ 
Fasciculations in extremities þ  þ þ þ þ þ 
Pyramidal signs þ  þ     þ
EMG þ  þ n.a. þ n.a. n.a. 
MRI/CT FTþ FþTþ FTþ Fþþ FTþ n.a. Fþ FþTþþ
SPECT FTþ n.a. FTþ n.a. n.a. FTþ Fþ n.a.
Note: þ, mild/moderate; þþ, severe; F, frontal; T, temporal; n.a., not available.
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coeruleus and pons, medulla and cerebellum and frozen at 80C.
Half of the brain was fixed in 10% buffered formalin solution for
4 weeks. Eight micrometres paraffin-embedded sections of the
same brain regions underwent routine staining with haematoxylin-
eosin, Bodian, methenamine silver and Congo red.
Primary antibodies were used for recognition of the following
proteins: hyperphosphorylated tau (AT8, Innogenetics, Ghent,
Belgium; 1 : 40), PHF1 (donated by P. Davies, Albert Einstein
College of Medicine, New York, USA; 1 : 100), antibodies directed
against ubiquitin (anti-ubiquitin, DAKO, Glostrup, Denmark;
1 : 500, following 80C antigen retrieval), b-amyloid protein
(anti-beta amyloid, DAKO, Glostrup, Denmark; 1 : 100, following
formic acid pre-treatment), a-synuclein (anti-a-synuclein, Zymed
Laboratories, San Francisco, California, USA; undiluted, following
formic acid pretreatment), CD68 (DAKO, Glostrup, Denmark;
1 : 200, following 80C antigen retrieval), p62 (BD Biosciences
Pharmingen, San Diego, CA, USA; 1 : 200, following 80C antigen
retrieval), TDP-43 (Biotech, Chicago, IL, USA; 1 : 100, following
pressure-cooking), glial fibrillary acidic protein (GFAP; DAKO,
Glostrup, Denmark; 1 : 500, following 80C antigen retrieval),
neurofilament (SMI-32, Sternberger Monoclonals, Lutherville,
MD, USA; 1 : 7000, following 80C antigen retrieval), and
NeuN (Chemicon, Temecula, CA, USA, 1 : 500, following high-
pressure cooking).
Additional immunohistochemistry of neuronal intranuclear
inclusions with antibodies against the nuclear proteins promye-
locytic leukaemia protein (PML, Santa Cruz Biotechnology
Inc., Santa Cruz, California, USA; 1 : 50, following pressure-
cooking), and small ubiquitin modifier-1 (SUMO-1, Santa Cruz
Biotechnology Inc., Santa Cruz, California, USA; 1 : 100,
following 80C antigen retrieval) was performed on sections
with NII.
Antigen retrieval was done either for 30min in 0.1M sodium
citrate buffer at 80C and pH 7.7 or using pressure-cooking in
0.1M sodium citrate buffer (pH 6) for 5min. Pretreatment with
99% formic acid was done for 5min (a-synuclein) or 20 s
(b-amyloid).
Primary antibodies were incubated overnight at 4C.
Endogenous peroxidase activity was inhibited by 30min incuba-
tion in PBS–hydrogen peroxide–sodium azide solution (100ml
0.1M PBSþ 2ml 30% H2O2þ 1ml natriumazide) and immuno-
histochemistry performed as described for paraffin-embedded
sections. The Histostain-Plus broad-spectrum kit DAB (Zymed,
San Francisco, CA, USA) was used as a detection system. Slides
were counterstained with Mayer’s haematoxylin and mounted in
Entellan.
Results
Demographic and clinical features
The Dutch FTD cohort consisted of 368 patients with FTD
(mean age at onset 57.8 9.2 years). Of 368 patients, 10
patients had sporadic FTDþMND and 8 patients had a
positive family history for dementia/FTD, MND or both
(44.4%). The mean age at onset in the FTDþMND group
(56.0 9.2 years) was similar to that of the FTD
group (57.9 9.2 years), whereas survival in the first
group (3.4 1.6 years) was significantly shorter than in
the latter (Table 2). From the group of FTD patients,
available brain tissue of 54 cases showed tauopathy in 28
cases, 14 FTDP-17T associated with MAPT mutations and
14 sporadic tauopathies (six Pick’s disease). Twenty-five of
the remaining 26 brains had FTLD-U, and one showed
neither tau- nor ub-positive inclusions (dementia lacking
distinctive histology, DLDH). Neuropathological examina-
tion in six FTDþMND patients (four familial, two
sporadic) was consistent with the clinical diagnosis
FTDþMND (see later).
The group of eight patients with familial FTDþMND
(mean age at onset 53.2 8.4 years), came from six families
with FTDþMND (Fig. 1). The mean age of onset and of
death in the eight familial FTDþMND did not differ from
those with sporadic FTDþMND. Five index patients
presented with behavioural changes or memory problems
followed by motor signs in three (interval 18.0 8.5
months). The remaining three index patients presented
with slurred, speech, swallowing difficulties and weakness of
extremities followed by dementia (interval 6.0 3.0 months).
One of the two patients with only FTD was still alive without
any motor neuron signs 5 years after onset (Family 2; II : 1).
The other patient with FTD (Family 6, II : 4) died from
bronchopneumonia after disease duration of 4 years, and
neuropathological examination showed features consistent
with FTDþMND (see later).
Neurological examination revealed muscle wasting in
interossei of the hands (n¼ 4), thighs (n¼ 2) or tongue
(n¼ 4) and fasciculations in arms (n¼ 6), hands (n¼ 3),
thighs (n¼ 4) or tongue (n¼ 5). EMG showed muscle
denervation (fibrillations, positive waves and fasciculations),
without the evidence of conduction block in the three
Table 2 Demographic data of the 350 patients with FTD and 18 patients with FTDþMND
Total FTD cohort (n¼ 368) P-value
FTD (n¼ 350) FTDþMND (n¼18)
Male : female 165 : 185 10 : 8 40.05
Onset (years) 57.9 9.2 56.0 9.2 40.05
Family history 162/350 (46.3%) 8/18 (44.4%) 40.05
Death (years) 66.4 9.4 (n¼ 205) 56.9 8.5 (n¼15)a 50.001
Survival (years) 9.03.9 (n¼ 205) 3.41.6 (n¼15)a 50.001
aThree patients with FTDþMND were still alive.
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investigated patients. Deep tendon reflexes and extensor
reflexes in upper and lower extremities were increased in
three patients. One of these patients had clinical FTD but
no lower motor neuron signs. Extrapyramidal signs were
absent in all patients at ascertainment and follow-up,
although none of the patients were examined in the final
stages of the disease.
Language deficits developed with disease progression in
seven patients, which consisted of impaired comprehension
(n¼ 6), reduced spontaneous speech (n¼ 5), word-finding
difficulties/impaired naming (n¼ 3), perseverations (n¼ 2)
and paraphasia (n¼ 2). Impaired attention and executive
functions (Wisconsin, Trailmaking, Stroop, Mazes),
decreased word fluency and perseverations were found,
whereas memory and visuoconstructive functions were
relatively preserved. Neuroimaging (MRI/CT) showed
mild symmetrical frontotemporal atrophy (n¼ 5) or mild
frontal atrophy (n¼ 2). SPECT performed in four patients
revealed frontal with or without temporal hypoperfusion in
all (Table 1).
Intrafamilial clinical variation
The occurrence of FTDþMND in four families was
suggestive for an autosomal dominant form, whereas the
mode of inheritance was uncertain in the remaining two
families with affecteds in one generation. The clinical
diagnosis was established on available data from medical
records in eight affected relatives (with neuropathological
reports in two), whereas the diagnosis in the remaining 12
affected relatives was based on clinical data obtained from
family members.
The six families showed considerable intrafamilial
variation in age at onset and clinical presentation. Of the
two ascertained patients from a single family (Family 2),
patient II:2 presented with FTDþMND, whereas his sister
did not have clinical features nor EMG signs of MND 5
years after onset of FTD. Additionally, of 20 affected
relatives from the six families, 11 had died from dementia/
FTD, eight from MND and one from MND with dementia
(Fig. 1).
Neuropathology
Brain autopsy became available in five patients with familial
FTDþMND, four with clinical FTDþMND (Family 1,
II : 3; Family 2, II : 2; Family 4, II : 1; Family 5, II : 2) and
one with clinical FTD (Family 6, II : 4); the two brains of
sporadic FTDþMND are excluded from this analysis. The
mean brain weight was 1214 163 g (not recorded in one).
Macroscopical inspection showed mild atrophy of frontal
lobes (n¼ 4) and severe atrophy of the temporal cortex
(n¼ 1). On coronal sections, the lateral ventricles were
dilated in three and normal in two patients.
Depigmentation of the substantia nigra was seen in two
patients.
Mild neuronal loss, gliosis and spongiosis were seen in
the superficial layers of the frontal cortex (n¼ 4), and of
the temporal cortex (n¼ 3). Neuronal loss was also present
in the substantia nigra (n¼ 3) and in hypoglossal nuclei
(n¼ 3), whereas brainstems at the level of hypoglossal
nuclei were not available for evaluation in the remaining
two brains (Table 3). The spinal cord showed loss of lower
motor neurons (n¼ 3) and degeneration of corticospinal
tracts with occasionally axonal torpedoes/spheroids and
foamy cells (n¼ 2).
Immunohistochemistry with tau antibodies stained a few
neurofibrillary tangles (NFT) in hippocampus (n¼ 3) and
temporal cortex (n¼ 2). Staining with ubiquitin antibody
showed ub-positive neuronal cytoplasmatic inclusions
(NCI) in the granular cells of the dentate gyrus in all
cases (Fig. 2A). The frontal and temporal cortex showed
many ub-positive NCI and dystrophic neurites in four
brains (Fig. 2C). Many ub-positive NCI in the striatum
= FTD + MND = Dementia / FTD
Family 1 Family 2
Family 3 Family 4 Family 5 Family 6
53
II:2
70 79
68
II:1
2
73
2 83
64
II:3
72 71 75
61 49 65 57
n
66
5
5
8
63
89 73
67 58 59 69
II:4
5
73
57
II:1
75
7
2
52 75
59 67 48 68
II:4
3
43
II:2
58 47
51
II:1
3
= MND
Fig. 1 Familial FTDþMND cases. Numbers are age of death or current age. Arrows indicate index patients.
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were seen in one brain (Fig. 3A), and some in the other
brains. Ub-positive NCI were not found in hypoglossal
nuclei or other brainstem nuclei in the three cases where
the brainstem at this level was available. Two brains showed
a low number of neuronal intranuclear inclusions (NII)
with lentiform or cat-eye shape in the frontal cortex,
the dentate gyrus and striatum. Ub-positive (skein-like)
inclusions were present in the spinal cord in all patients
(Fig. 2E), including the patient with clinical FTD during life
(Family 6, II:4, see above). The ubiquitin pathology
consisting of numerous NCI is consistent with type 2
of Sampathu et al., and with type 3 of Mackenzie et al.
(Mackenzie et al., 2006a; Sampathu et al., 2006), although
the presence of NII in two cases fits more into type 3 and
type 1, respectively.
Staining with the TDP-43 antibody showed a robust
staining of NCI in the dentate gyrus, frontal and temporal
cortex, and spinal cord (Table 3 and Fig. 2B, D and F).
The morphology of TDP-43 inclusions resembled
ub-positive NCI. TDP-43 antibody also stained NII
found in the two cases with ub-positive NII (Fig. 3C
and D). Nuclei of unaffected neurons showed TDP-43
staining, which was not observed in neurons positive for
TDP-43 with NCI. Neurons in the olivary nucleus showed
strong nuclear TDP-43 staining in one brain. Positive
TDP-43 staining of ub-negative glial inclusions was seen in
the basal striatum of a single brain (Fig. 3B), whereas ub-,
TDP-43 positive NCI in the striatum were seen in all five
brains (Fig. 3A). TDP-43 positive glial cells had small
dark-blue nuclei and were often located within the white
matter. In addition, serial 4 mm sections of the striatum
with glial inclusions stained with TDP-43 and NeuN
antibodies, respectively, clearly distinguished TDP-43
positive glial cells from small neurons. The p62 antibody
stained both ub-positive and TDP-43 positive NCI and
TDP43-positive, ub-negative glial inclusions. The SUMO-1
Table 3 Pathology and TDP-43 staining
Family 1 Family 2 Family 4 Family 5 Family 6
II : 3 II : 2 II : 1 II : 2 II : 4
Gross findings
Weight (g) 1076 1260 1425 1096 n.a.
Atrophy
Frontal þ þ  þ 
Temporal     þþ
Substantia nigra  þ   þ
Microscopy/immunohistochemistry
Frontal
Neuronal loss/gliosis þ þ  þ þ
NCI þ þþ  þ þ
NII     þ
Temporal
Neuronal loss/gliosis  þ  þ þþ
NCI þþ þ  þþ þ
NII     
Hippocampus
Neuronal loss/gliosis  þþ  þ 
NCI þþ þþ þ þ 
NII þ    
Striatum
Neuronal loss/gliosis þ    
NCI þþ þ þ þþ þ
NII þ    þ
Glial inclusions    þ 
Substantia nigra
Neuronal loss/gliosis þþ þþ þ þþ 
NCI  þ þ þ þ
NII     
Spinal cord/lower motor neurons
Neuronal loss/gliosis þ þ þ  
NCI þ þ þ þ þ
NII     
Nucleus hypoglossus
Neuronal loss/gliosis þþ þ n.a. þ n.a.
NCI     
NII     
NCI, neuronal cytoplasmatic inclusions; NII, neuronal intranuclear inclusions; n.a., not available; , none; þ, mild/moderate; þþ, severe.
DenotesTDP-43 positive, ub-negative glial inclusions.
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antibody stained NII in the two brains, whereas PML
staining of NII was negative in both cases. Staining with
b-amyloid showed a few senile plaques in the temporal
cortex of two patients. The corticospinal tracts in the
spinal cord of three patients showed many CD68-positive
cells. A few neurons with Lewy bodies and few Lewy
neurites in the substantia nigra of two brains were
visualized with a-synuclein staining.
DNA analysis
Genetic analysis did not show any mutations in the MAPT
and PGRN genes in the eight patients with familial
FTDþMND, whereas their frequency in the total FTD
group was 10.3 and 5.7%, respectively. No mutations were
found in CHMP2B, SOD1, ANG, VCP or DCTN1 genes.
Discussion
The present study described the occurrence of FTDþMND
in 4.3% of a large FTD cohort in the Netherlands. Familial
FTDþMND found in 44.4% of cases showed considerable
intrafamilial clinical variation. TDP-43 antibody showed
robust staining of neuronal cytoplasmatic ub-positive
inclusions in five available brains, and also of ub-negative
glial inclusions in one brain. Rare neuronal intranuclear
inclusions were found in neocortex, hippocampus and
striatum of two brains, despite the absence of mutations in
the progranulin gene.
Our observation that 44.4% of the FTDþMND cases in
our cohort had a positive family history, is similar to that
reported in other studies (Chow et al., 1999; Goldman et al.,
2005). The considerable clinical variation within the present
families occurred between generations as well as within the
same generation, as reported in familial FTDþMND with
unknown genetic locus or linked to chromosomes 9 and 17
(Gunnarsson et al., 1991; Chow et al., 1999; Wilhelmsen et al.,
2004; Martinaud et al., 2005). Some affected individuals
presented with behavioural changes and executive dysfunc-
tions (Barson et al., 2000), localized frontal atrophy on MRI
scan (Ikeda et al., 2002; Chang et al., 2004, 2005; Jeong et al.,
Fig. 2 Positive staining with anti-ubiquitin and TDP-43 antibody of neuronal cytoplasmatic inclusions in the granular cells of the dentate
gyrus was seen in the hippocampus in all cases with ubiquitin (A) and TDP-43 (B). NCI in the neocortex with ubiquitin (C) and TDP43 (D)
and (skein-like) inclusions were seen in all spinal cords with both ubiquitin (E) and TDP-43 (F). Scale bar¼100mm.
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2005; Toyoshima et al., 2005; Whitwell et al., 2006), whereas
other patients had muscle wasting and dysarthria as the initial
symptoms (Ikeda et al., 2002; Toyoshima et al., 2005; Josephs
et al., 2006a). In our view, the phenomenon of clinical
variation within families with FTDþMND warrants the
combined analysis of patients with FTD, MND or
FTDþMND.
The robust TDP-43 staining of neuronal cytoplasmatic
ub-positive inclusions in the present study strongly
supports the hypothesis that the TDP-43 protein is
substantial constituent of ub-positive inclusions (Arai
et al., 2006; Neumann et al., 2006). These TDP-43
inclusions showed a morphology similar to that of
ub-positive inclusions and their pattern was consistent
with ubiquitin pathology type 2, as reported by Sampathu
(Sampathu et al., 2006) or type 3 reported by Mackenzie
(Mackenzie et al., 2006a). In our view, the presence of a few
NII in two of our FTDþMND cases should not result in a
reclassification. In contrast to the more granular aspect of
neuronal inclusions in the dentate gyrus of cases with
PGRN mutations (Mackenzie et al., 2006b), the ub- and
TDP-43-positive inclusions in our brains had a more solid
consistency. Skein-like inclusions in motor neurons of the
spinal cord were not only found in patients with clinical
FTDþMND (Mackenzie and Feldman, 2005; Josephs et al.,
2006a), but also in FTD patients without signs of
MND confirming earlier observations (Ikeda et al., 2002;
Josephs et al., 2006a). An interesting phenomenon is the
negative TDP-43 nuclear staining of ub-containing neurons
in contrast to positive nuclear staining of normal
neurons (Neumann et al., 2006). The question is whether
the TDP-43 protein moved from the nucleus to the
cytoplasm during the disease process or that modified
TDP-43 isoforms in the cytoplasm of specific neurons never
entered the nucleus, as has recently been proposed by
Davidison et al. (Davidson et al., 2007). In both situations,
a loss of TDP-43 nuclear function could be responsible for
the disease. As TDP-43 is involved in splicing of pre-
mRNA, future studies should attempt to identify target
mRNAs of TDP-43 in order to elucidate the pathophysio-
logical mechanisms.
The most interesting observation is the presence of rare
neuronal intranuclear inclusions in two of the present
familial FTDþMND cases without PGRN mutations,
although large deletions could not be excluded by the use
of conventional sequencing techniques in this study.
Previous studies have reported these NII in FTD families
without MND (Rosso et al., 2001a; Woulfe et al., 2001;
Mackenzie et al., 2006c; Pirici et al., 2006). After the
identification of PGRN gene mutations in these families
(Baker et al., 2006; Cruts et al., 2006), their presence was
considered to be specific for these gene defects (Mackenzie
et al., 2006b). In a few studies however, they were also
found in familial FTDþMND cases, although at that time
the genetic defect was still unknown (Woulfe et al., 2001;
Bigio et al., 2004; Katsuse and Dickson, 2005). Our
observation supports the idea that the presence of intra-
nuclear inclusions are not exclusively restricted to cases
with PGRN mutations (Mackenzie et al., 2006b). The
positive SUMO-1 of NII in the present two cases confirms
the observations by Mackenzie et al. and had also been
found in other neurodegenerative disorders (Pountney
Fig. 3 Ub-positive neuronal cytoplasmatic inclusions were found in the caudatus (A) and the glial cells stained positive withTDP-43 (B).
Lentiform or cat-eye shaped NII in the dentate gyrus (C) and neocortex (D) also stained positive withTDP-43. Scale bar¼100mm.
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et al., 2003; Mackenzie et al., 2006c). This ubiquitin-like
protein, SUMO-1, appears to be involved in the nuclear
proteasomal degradation (Pountney et al., 2003). The
negative PML-staining of NII has to be further investigated
in other series, as previous studies have shown inconclusive
results (Pountney et al., 2003; Mackenzie et al., 2006c).
Another very interesting finding was the presence of
TDP-43-positive, ub-negative glial cytoplasmatic inclusions
in the striatum of a single brain. Very recently, the
polyclonal TDP-43 antibody has shown positive staining
of glial inclusions in the grey matter and spinal cord of
FTDþMND (Arai et al., 2006). This suggests that glial cells
may be involved in the pathophysiological process of the
disease. Future immunohistochemical and biochemical
studies in FTD and FTDþMND cases are needed to
investigate the significance of glial pathology.
The pyramidal tract degeneration in one of the present
patients indicates that the neurodegeneration in FTD
may extend to upper and lower motor neuron system in
patients living long enough, as suggested earlier (Holton
et al., 2002; Ikeda et al., 2002; Toyoshima et al., 2005;
Josephs et al., 2006a). Neuron loss of the substantia nigra
and striatum in several of the present cases also shows
that the pathological process is more widespread than the
motor system alone (Konagaya et al., 1998; Tsuchiya et al.,
2001; Al-Sarraj et al., 2002; Ikeda et al., 2002; Bigio
et al., 2004; Katsuse and Dickson, 2005; Mackenzie and
Feldman, 2005; Toyoshima et al., 2005), although the
presence of extrapyramidal signs is an uncommon feature
in the present and other studies (Mitsuyama, 1993;
Mackenzie and Feldman, 2004).
Whereas a genetic locus on chromosome 9p has been
found for several families with an autosomal dominant
form of FTD, MND or FTDþMND in affected sibs, the
present families were too small for significant linkage.
Studies with a genome-wide scan using single nucleotide
polymorphisms in these small families will be performed in
the future.
In conclusion, there exists considerable intrafamilial
variation in FTDþMND, which should be explained by
yet unidentified genetic and environmental factors. The
significance of neuronal intranuclear inclusions and TDP-
43 glial inclusions in some of the present FTDþMND
cases has to be determined in future studies. To elucidate
the role of the TDP-43 protein in the pathophysiology
might hopefully explain the considerable variation in
clinical phenotype.
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